BAKER BROS. ADVISORS LP Q4 2016 Filing
Filed February 14, 2017
Portfolio Value
$10.2B
Holdings
133
Report Date
Q4 2016
Filing Type
13F-HR
All Holdings (133 positions)
| # | Stock | Shares | Value | % Portfolio | Type |
|---|---|---|---|---|---|
| 101 | —MyoKardia, Inc. | 100,000 | $1.3B | 12.69% | |
| 102 | QUREuniQure N.V. | 230,000 | $1.3B | 12.63% | |
| 103 | MCRB1EURSeres Therapeutics, Inc. | 125,000 | $1.2B | 12.14% | |
| 104 | —Colucid Pharmaceuticals, Inc. | 30,310 | $1.1B | 10.81% | |
| 105 | —Ritter Pharmaceuticals, Inc. | 400,000 | $1.1B | 10.63% | |
| 106 | PRQRProQR Therapeutics N.V. | 212,698 | $1.0B | 10.21% | |
| 107 | —Palatin Technologies, Inc. | 2,050,000 | $1.0B | 10.15% | |
| 108 | —MediWound Ltd. | 226,000 | $1.0B | 10.15% | |
| 109 | —Five Prime Therapeutics, Inc. | 19,247 | $964.0M | 9.45% | |
| 110 | MDGLMadrigal Pharmaceuticals, Inc. | 57,762 | $861.0M | 8.44% | |
| 111 | CLLSCellectis S.A. | 50,000 | $848.0M | 8.31% | |
| 112 | —Immune Design Corp. | 148,937 | $819.0M | 8.03% | |
| 113 | —Tenax Therapeutics, Inc. | 420,000 | $819.0M | 8.03% | |
| 114 | INFIQInfinity Pharmaceuticals, Inc. | 580,400 | $784.0M | 7.69% | |
| 115 | ALDXAldeyra Therapeutics, Inc. | 142,000 | $760.0M | 7.45% | |
| 116 | —Proteon Therapeutics, Inc. | 389,394 | $740.0M | 7.25% | |
| 117 | XLRNAcceleron Pharma Inc. | 28,765 | $734.0M | 7.20% | |
| 118 | —Affimed N.V. | 400,000 | $720.0M | 7.06% | |
| 119 | CBAYUSDCymaBay Therapeutics, Inc. | 309,268 | $535.0M | 5.24% | |
| 120 | CMRXEURChimerix, Inc. | 115,216 | $530.0M | 5.20% | |
| 121 | I9DNArbutus Biopharma Corporation | 180,582 | $442.0M | 4.33% | |
| 122 | ALNYAlnylam Pharmaceuticals, Inc. | 11,340 | $425.0M | 4.17% | |
| 123 | ADAPYAdaptimmune Therapeutics plc | 100,000 | $405.0M | 3.97% | |
| 124 | —Foundation Medicine, Inc. | 20,892 | $370.0M | 3.63% | |
| 125 | —BioDelivery Sciences International, Inc. | 210,021 | $368.0M | 3.61% | |
| 126 | CCXIEURChemoCentryx, Inc. | 49,064 | $363.0M | 3.56% | |
| 127 | —Aptose Biosciences Inc. | 258,311 | $359.0M | 3.52% | |
| 128 | —Windtree Therapeutics, Inc. | 254,973 | $319.0M | 3.13% | |
| 129 | —ProNAi Therapeutics, Inc. | 200,000 | $298.0M | 2.92% | |
| 130 | DVAXDynavax Technologies Corporation | 75,000 | $296.0M | 2.90% | |
| 131 | —La Jolla Pharmaceutical Company | 13,746 | $241.0M | 2.36% | |
| 132 | BGMS 6 PERPCyclacel Pharmaceuticals, Inc. | 13,253 | $82.0M | 0.80% | |
| 133 | —BioTime, Inc. | 20,084 | $14.0M | 0.14% |
PreviousPage 2 of 2